Skip to Content

Generic Vitekta Availability

Vitekta is a brand name of elvitegravir, approved by the FDA in the following formulation(s):

VITEKTA (elvitegravir - tablet;oral)

  • Manufacturer: GILEAD SCIENCES INC
    Approval date: September 24, 2014
    Strength(s): 85MG, 150MG [RLD]

Has a generic version of Vitekta been approved?

No. There is currently no therapeutically equivalent version of Vitekta available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vitekta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 4-oxoquinoline compound and use thereof as pharmaceutical agent
    Patent 7,176,220
    Issued: February 13, 2007
    Inventor(s): Satoh; Motohide & Kawakami; Hiroshi & Itoh; Yoshiharu & Shinkai; Hisashi & Motomura; Takahisa & Aramaki; Hisateru & Matsuzaki; Yuji & Watanabe; Wataru & Wamaki; Shuichi
    Assignee(s): Japan Tobacco Inc.
    An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.
    Patent expiration dates:
    • November 20, 2023
      ✓ 
      Patent use: TREATMENT OF HIV INFECTION
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Stable crystal of 4-oxoquinoline compound
    Patent 7,635,704
    Issued: December 22, 2009
    Inventor(s): Satoh; Motohide & Motomura; Takahisa & Matsuda; Takashi & Kondo; Kentaro & Ando; Koji & Matsuda; Koji & Miyake; Shuji & Uehara; Hideto
    Assignee(s): Japan Tobacco Inc.
    Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2θ(°) as measured by X-ray powder diffractmetry.
    Patent expiration dates:
    • October 26, 2026
      ✓ 
      Patent use: TREATMENT OF HIV INFECTION
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Stable crystal of 4-oxoquinoline compound
    Patent 8,981,103
    Issued: March 17, 2015
    Assignee(s): Japan Tobacco Inc.
    Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2θ(°) as measured by X-ray powder diffractometry.
    Patent expiration dates:
    • October 26, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • September 24, 2017 - NEW PRODUCT

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide